Sun Pharma scrip tanks 6.5% on USFDA ban

Updated - May 23, 2016 04:10 pm IST

Published - March 13, 2014 01:39 pm IST - Mumbai

Shares of Sun Pharmaceuticals on Thursday slumped by as much as 6.5 per cent following a ban on import of products made at its Karkhadi plant in Gujarat by the U.S. Food and Drug Administration due to violation of manufacturing norms.

After opening on the positive note, shares of the drug firm went into a tailspin following the ban and plunged 6.35 per cent to Rs. 565.60 at the BSE.

On the NSE, the stock slipped 6.42 per cent to Rs. 565.50.

According to the information available on USFDA website, the regulator has issued an import alert, which enables ’detention without physical examination of drugs from firms which have not met drug GMPs’

Comments from the company could not be obtained immediately.

This is the first import alert for any of Sun Pharma’s plants from the USFDA, which has been cracking down heavily on firms such as Ranbaxy and Wockhardt that have not complied with its manufacturing norms.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.